Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics

ABSTRACT: Ritlecitinib is a selective, covalent, irreversible inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases. Pharmacokinetics and safety of ritlecitinib in participants with hepatic (Study 1) or renal (Study 2) impairment were t...

Descripción completa

Detalles Bibliográficos
Autores principales: Purohit, Vivek, Huh, Yeamin, Wojciechowski, Jessica, Plotka, Anna, Salts, Stephanie, Antinew, Jeremias, Dimitrova, Angela, Nicholas, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047454/
https://www.ncbi.nlm.nih.gov/pubmed/36977960
http://dx.doi.org/10.1208/s12248-023-00792-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047454/
https://www.ncbi.nlm.nih.gov/pubmed/36977960
http://dx.doi.org/10.1208/s12248-023-00792-8

Ejemplares similares